Renanolone

An obscure 1970s intravenous steroid anaesthetic; the 5beta epimer of alphaxalone and a low-potency GABA-A neurosteroid modulator.

Renanolone was never approved for human use, and no modern controlled safety data exist; assessment rests on the pharmacology of the steroid-anaesthetic class to which it belongs. As a positive modulator of inhibitory GABA-A signalling it would be expected to cause dose-dependent central nervous system depression, respiratory depression and hypotension, the same limiting effects seen with intravenous anaesthetics generally.

The greatest historical hazard of this class came not from the steroid but from its formulation; because these molecules are almost insoluble in water they were dissolved in polyethoxylated castor oil (Cremophor EL), a vehicle that triggered histamine release and occasionally severe anaphylactoid reactions, and this liability led to the withdrawal of the related product Althesin in 1984. Steroid anaesthetics have also been associated with excitatory phenomena such as tremor and involuntary muscle movements during induction. Renanolone should be regarded strictly as a historical and laboratory reference compound with no established human dosing and no legitimate consumer use.

The idea that steroids can produce anaesthesia dates to 1941, when Hans Selye reported rapid hypnosis in rodents given progesterone and related steroids. The first clinically used steroid anaesthetic was hydroxydione (Viadril), a water-solubilised 5beta-pregnanedione introduced in the mid-1950s, but its slow onset and venous irritation limited its use. The decisive advance came from the Glaxo laboratories, where systematic synthesis and screening of pregnane analogues yielded alphaxalone and its solubilising partner alfadolone acetate; the combination, formulated in Cremophor EL as CT1341, reached the clinic as Althesin in 1971 and became a widely used intravenous anaesthetic.

Renanolone was one of the numerous analogues generated in and around this program; as the 5beta epimer of alphaxalone it entered pharmacological and early clinical evaluation but was not selected for development, and reference databases record it as having advanced only to early-phase clinical study. The structure-activity surveys of Gyermek in 1968 and of Phillipps in 1975 catalogued renanolone and its relatives and helped define the stereochemical rules of the series.

Interest in steroid anaesthesia waned after Althesin was withdrawn in 1984 over Cremophor reactions, then revived through alternative formulations such as the pregnanolone emulsion eltanolone and, more recently, cyclodextrin-solubilised alphaxalone (Phaxan). Renanolone itself survived only as a footnote and comparator within this history.

Renanolone has essentially no public profile; it is not a supplement, has never been marketed, and has no recreational following or commercial availability. Within neuropharmacology it is known narrowly as the 5beta epimer of alphaxalone and as a low-potency member of the steroid-anaesthetic series, cited chiefly in structure-activity discussions and, more recently, as a competitor used to map neurosteroid binding sites on the GABA-A receptor. Its enduring value is didactic, since it demonstrates how strictly neurosteroid activity depends on ring-fusion stereochemistry and the 3alpha-hydroxyl configuration. Claims of nootropic or cognitive-enhancing benefit have no basis, because its pharmacology is sedative and anaesthetic rather than stimulant or pro-cognitive.